NCT00105079 - GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection | Biotech Hunter

Enrollment

337

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

August 31, 2007

Study Completion Date

July 31, 2008

Conditions

HIV Infections

Interventions

DRUG

saquinavir [Invirase]

1000 milligram (mg) Oral (po) twice daily (bid)

DRUG

Lopinavir/ritonavir

Lopinavir/ritonavir 400/100 mg po bid

DRUG

Emtricitabine/tenofovir disoproxil fumarate

Emtricitabine/tenofovir disoproxil fumarate 200/300 mg po qd

DRUG

Ritonavir

100 mg po bid

Trial Locations (44)

10011

New York

10330

Bangkok

13009

Marseille

13385

Marseille

19107

Philadelphia

20009

Washington D.C.

28078

Huntersville

30309

Atlanta

31052

Toulouse

31201

Macon

32204

Jacksonville

32803

Orlando

32960

Vero Beach

33136

Miami

36201

Hobson City

44035

Nantes

48197

Ypsilanti

59208

Tourcoing

60613

Chicago

63139

St Louis

67091

Strasbourg

69288

Lyon

69437

Lyon

73031

Rouen

75010

Paris

75014

Paris

75651

Paris

77004

Houston

84902

Avignon

85745

Tucson

90028

Los Angeles

92150

Suresnes

94705

Berkeley

07102

Newark

L8N 3Z5

Hamilton

K1H 8L6

Ottawa

M4N 3M5

Toronto

M5B 1L6

Toronto

M5G 2C4

Toronto

H2L 4P9

Montreal

H2L 5B1

Montreal

H2X 2P4

Montreal

06202

Nice

00717-1563

Ponce

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY